Logoclonia might be a Characteristic of Logopenic Variant Primary Progressive Aphasia at an Advanced Stage: Potential Mechanisms Underlying Logoclonia.

Alzheimer’s disease logoclonia logopenic variant primary progressive aphasia naming abilities phonological output

Journal

Journal of Alzheimer's disease : JAD
ISSN: 1875-8908
Titre abrégé: J Alzheimers Dis
Pays: Netherlands
ID NLM: 9814863

Informations de publication

Date de publication:
2019
Historique:
pubmed: 10 6 2019
medline: 2 10 2020
entrez: 10 6 2019
Statut: ppublish

Résumé

Logoclonia, which is the meaningless repetition of a syllable, particularly an end syllable of a word, has been described in patients with dementia for a century. The mechanisms behind logoclonia, however, have yet to be clarified. Among 914 patients with aphasia, five patients presented with logoclonia, all of whom were categorized as having logopenic variant PPA (lvPPA) during the initial stage of their illness and met the clinical criteria for diagnosis of probable Alzheimer's disease. Cognitively, they were all severely impaired when they presented with logoclonia. During the progression from lvPPA to logoclonia in these patients, their naming abilities and phonological output function deteriorated despite their retained speech fluency. Logoclonia might be a characteristic sign of advanced-stage lvPPA. Although logoclonia might be associated with perseveration, deterioration in naming abilities and phonological output function along with retained speech fluency might form the basis for the development of logoclonia.

Identifiants

pubmed: 31177224
pii: JAD190184
doi: 10.3233/JAD-190184
pmc: PMC6700633
doi:

Types de publication

Case Reports Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

515-524

Références

J Neurol Neurosurg Psychiatry. 1999 Jun;66(6):776-8
pubmed: 10329754
Psychiatry. 1999 Summer;62(2):138-72
pubmed: 10420428
Brain Lang. 2000 Jan;71(1):255-7
pubmed: 10716858
No To Shinkei. 2000 Nov;52(11):1035-44
pubmed: 11217688
Rinsho Shinkeigaku. 1992 Aug;32(8):859-63
pubmed: 1490313
Brain Cogn. 2005 Feb;57(1):8-15
pubmed: 15629207
Neuropathology. 2005 Mar;25(1):107-9
pubmed: 15822827
Braz J Med Biol Res. 2006 Mar;39(3):371-85
pubmed: 16501817
Neurology. 2008 Oct 14;71(16):1227-34
pubmed: 18633132
Brain. 2009 Dec;132(Pt 12):3411-27
pubmed: 19942676
Proc R Soc Med. 1947 Aug;40(10):552
pubmed: 20344682
Cogn Neuropsychol. 2000 Sep 1;17(6):517-46
pubmed: 20945193
J Mem Lang. 2010 Nov 1;63(4):541-559
pubmed: 21076661
Neurology. 2011 Mar 15;76(11):1006-14
pubmed: 21325651
Cortex. 2013 Mar;49(3):658-67
pubmed: 22482693
Cortex. 1990 Mar;26(1):41-63
pubmed: 2354645
BMC Neurol. 2013 Nov 01;13:158
pubmed: 24176108
Folia Phoniatr (Basel). 1985;37(5-6):246-58
pubmed: 2419231
J Psycholinguist Res. 1989 Mar;18(2):163-80
pubmed: 2472483
Brain. 2014 Dec;137(Pt 12):3248-66
pubmed: 25348632
Neurology. 2015 Jan 6;84(1):101
pubmed: 25548236
Cortex. 2015 Jun;67:122-33
pubmed: 25955499
Cortex. 2015 Aug;69:68-75
pubmed: 25989443
Cogn Behav Neurol. 2015 Dec;28(4):229-41
pubmed: 26705270
Rinsho Shinkeigaku. 1989 May;29(5):617-21
pubmed: 2676308
Alzheimers Res Ther. 2016 Dec 5;8(1):52
pubmed: 27915998
Curr Neurol Neurosci Rep. 2017 Aug;17(8):58
pubmed: 28656532
J Fluency Disord. 2018 Sep;57:51-58
pubmed: 29157667
Am J Speech Lang Pathol. 2018 Mar 1;27(1S):336-349
pubmed: 29497748
Arch Neurol. 1983 Mar;40(3):175-7
pubmed: 6830460
Acta Psychiatr Scand. 1982 Mar;65(3):194-209
pubmed: 7072512
Brain Lang. 1982 Sep;17(1):73-91
pubmed: 7139272
Neurology. 1993 Nov;43(11):2412-4
pubmed: 8232972
J Commun Disord. 1996 Nov-Dec;29(6):471-7; quiz 477-8
pubmed: 8956103
Hum Genet. 1998 Mar;102(3):253-7
pubmed: 9544835

Auteurs

Yoshitaka Nakagawa (Y)

Department of Rehabilitation, Edogawa Hospital, Tokyo, Japan.

Michitaka Funayama (M)

Department of Neuropsychiatry, Ashikaga Red Cross Hospital, Tochigi, Japan.

Masahiro Kato (M)

Department of Neurology, Edogawa Hospital, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH